Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Efruxifermin, Novel Therapy Discovered for Nonalcoholic Steatohepatitis (NASH)

Akero Therapeutics, discovered novel Efruxifermin for the treatment of nonalcoholic steatohepatitis (NASH).

Efruxifermin (EFX) also known to be AKR-001, currently being evaluated in the ongoing Phase 2b HARMONY study is the main leading candidate for NASH. EFX is a novel therapy developed to reverse fibrosis, to reduce liver fat and inflammation, increase insulin sensitivity, and improve lipoproteins.

It has the ability to treat complicated, multi-system disease state of NASH together with improvements in lipoprotein risk factors linked to cardiovascular disease, the leading cause of death in NASH patients.

Nonalcoholic steatohepatitis (NASH) is a serious liver disease approximately affecting 17 million Americans. Currently there are no approved treatments for NASH and it is the fastest growing cause of liver transplants and liver cancer in the countries like US and Europe.

NASH generally results in accumulation of fat in the liver causing stress and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death.

US Food and Drug Administration (FDA) grants breakthrough designation for Efruxifermin for the treatment of nonalcoholic steatohepatitis (NASH).

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024